Bacterial (Vibrio) and Viral (Infectious Salmon Anemia) in Salmon Aquaculture
The aquaculture of salmonids is the farming and harvesting of salmonids under controlled conditions for both commercial and recreational purposes. Salmonids are the most important fish group in aquaculture (annual production of over 500,000,000). The most common commercially farmed salmonid is the Atlantic salmon. In 2011 the aquaculture of salmonids was worth over
US$130 billion globally. Salmonid aquaculture production grew over ten-fold during the 25 years from 1982 to 2007.
Bacterial infections caused by certain Vibrio species and the Infectious Salmon Anemia (ISA) virus seriously affect salmon farms in Chile, Norway, Scotland and Canada, causing major economic losses to infected farms (over $300 million). These diseases are highly lethal and, in the worst cases, death rates may approach 100%. They are also a threat to the dwindling stocks of wild salmon.
The possible emergence of pandemic bacterial and viral infections in cultivated Atlantic salmon is a serious concern for the aquaculture industry. Consequently, improving the effectiveness and safety of vaccines and immunotherapy to prevent or reduce the severity of salmon infections is of primary importance to producers and health officials. IMT504 has that potential.
Current Unmet Medical Need
Current vaccines for salmon bacterial and viral infections are of limited utility and the current vaccines are nowhere near 100%. These vaccines are neither effective nor safe. Sometimes the vaccines used may not protect against the relevant virus or viruses that are circulating. In addition, current vaccines for salmon infections are inadequate due to their:
-Limited amount of protection (efficacy)
-Limited period of protection at early age and over time
-Limited duration of antibody response
-Vaccines may not be available for many types of bacteria and viruses
PAH Medical Solution and Competitive Advantage
IMT504 has the potential to provide a set of vaccines and immunotherapy that will have:
-Vastly greater levels of protection (much higher antibody levels and longer duration of antibody protection)
-Broader cross-protection against other strains due to the diversification of antibody created by IMT504 via stimulation of activation-induced cytidine deaminase (an enzyme that is critical to optimization and diversification of antibody)
-Prolonged period of protection
-Superior safety profile
-Could be used to produce vaccines more efficiently and economically due to antigen dose-sparing